|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Ranbaxy_Laboratories
U. S. rights to the drug Azor
U. S. rights to the drug Benicar
U. S. rights to the drug Edarbi
U. S. rights to the drug Tribenzor
U. S. rights to the drug Welchol
|
|
gptkbp:ceo
|
gptkb:Yoshihiro_Kato
gptkb:Kiyoshi_Saito
gptkb:Masashi_Miyamoto
gptkb:Sunao_Manabe
gptkb:Toshio_Takahashi
|
|
gptkbp:founded
|
1897
|
|
gptkbp:founder
|
gptkb:Kōsuke_Matsumoto
|
|
gptkbp:global_presence
|
gptkb:Yes
|
|
gptkbp:headcount
|
Approximately 15,000 employees
|
|
gptkbp:headquarters
|
gptkb:Tokyo,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Daiichi Pharmaceutical
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:market_cap
|
Approximately $20 billion
|
|
gptkbp:parent_company
|
gptkb:Daiichi_Sankyo
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Merck_&_Co.
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:philanthropy
|
gptkb:Daiichi_Sankyo_Foundation_of_Life_Science
gptkb:Daiichi_Sankyo_Global_Health_Foundation
gptkb:Daiichi_Sankyo_Healthcare_Foundation
gptkb:Daiichi_Sankyo_Institute_of_Biomedical_Science
gptkb:Daiichi_Sankyo_Research_Institute_of_Japan
|
|
gptkbp:products
|
Prescription drugs
Over-the-counter drugs
|
|
gptkbp:research_focus
|
gptkb:diabetes
gptkb:Cardiovascular_diseases
gptkb:Oncology
Infectious diseases
|
|
gptkbp:stock_exchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:stock_symbol
|
4568
|
|
gptkbp:subsidiary
|
gptkb:Daiichi_Sankyo_Europe_Gmb_H
gptkb:Daiichi_Sankyo,_Inc.
gptkb:Daiichi_Sankyo_UK_Ltd.
gptkb:Daiichi_Sankyo_Canada_Inc.
gptkb:Daiichi_Sankyo_India_Pharma_Pvt._Ltd.
|
|
gptkbp:website
|
www.daiichipharmaceutical.com
|
|
gptkbp:bfsParent
|
gptkb:Daiichi_Sankyo
|
|
gptkbp:bfsLayer
|
5
|